GLP-1 medications do not just slow things down
With approximately 100 million American adults living with obesity, the availability of an oral GLP-1 option could significantly expand access to these highly effective medications
The organizations that will be most successful are not simply saying "yes" or "no" to coverage
doi: 10.2174/18715273113126660137 [DOI] [PMC free article] [PubMed] [Google Scholar] 110.Akiyama H, Barger S, Barnum S, et al
So, when the sugar levels rise after eating, it allows cells to absorb glucose
For someone with a functional gastrointestinal disorder like IBS, these signals can either be a source of relief or a potential trigger for discomfort, depending on their specific symptoms